GlassScriptPhysician profile
Mohiman Saffar
NPI 1952838138
$1,577.59
in general payments reported to CMS, 2019-2025
16 companies · $926 in 2025
The $926 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $51.48 · 2024: $600 · 2025: $926.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,578.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,577.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $397.70 | 2024-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $273.36 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Exact Sciences Corporation | $193.91 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Lilly USA, LLC | $153.99 | 2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $134.52 | 2023-2025 | |
| Sanofi Pasteur INC. | $124.87 | 2025 | |
| Glaxosmithkline, LLC. | $51.63 | 2024 | Trelegy Ellipta |
| Corcept Therapeutics | $44.64 | 2025 | Korlym |
| Abbott Laboratories | $40.18 | 2025 | Freestyle Libre 3 |
| Actelion Pharmaceuticals US, INC. | $38.24 | 2024-2025 | Uptravi, Opsumit |
| Hologic Sales and Service, LLC | $24.62 | 2025 | Thinprep 2000 Processor, Aptima |
| Olympus America INC. | $23.74 | 2025 | Itind System |
| Vertex Pharmaceuticals Incorporated | $23.45 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.73 | 2024 | Jardiance |
| Cranial Technologies, INC | $16.33 | 2025 | Doc Band |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dynavax Technologies Corporation | $13.68 | 2023 | Heplisav-B |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohiman Saffar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.